All In Biotech

Drug Trial Radar · NCT02947867

Trial of Aganirsen in iCRVO Patients at Risk of Developing NVG

Prospective, Randomised, Placebo-controlled, Double-masked, Three-armed Multi-centre Trial of Aganirsen Versus Vehicle in Patients After Ischaemic Central Retinal Vein Occlusion With a High Risk to Develop Neovascular Glaucoma

Last checked: Nov 19, 2026Latest source record: Oct 31, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 333 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

333

Planned (sponsor's estimate)

Start

Jan 2017

Primary completion

Jun 2019

Study completion Dec 2019

Sponsor

Lead sponsor
Gene Signal SASIndustry
Sponsor type
Industry
Collaborators
Johannes Gutenberg University Mainz; University Hospital of Cologne; Moorfields Eye Hospital NHS Foundation Trust
First posted
Oct 28, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A prospective, randomised, placebo-controlled, double-masked, three-armed multi-centre phase II/III trial for the Study of a Topical Treatment of Ischaemic Central Retinal Vein Occlusion to Prevent Neovascular Glaucoma - the STRONG Study

Conditions

  • Ischaemic Central Retinal Vein Occlusion
  • Neovascular Glaucoma

Interventions

  • aganirsenDrug

    aganirsen antisense oligonucleotide against Insulin Receptor Substrate (IRS-1)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. NVG componentTime frame: Week 24
  2. IOP componentTime frame: Week 24

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.